In order to provide the best software and product support for our customers, QIAGEN must periodically retire older versions of our software. This enables us to dedicate all our resources in delivering the latest features, enhancements and support to our current versions and latest solutions.
At this time, we would like to announce the pending end of life of QIAGEN Ingenuity Variant Analysis (IVA). On December 31, 2020, Adobe will end support of Flash Player, the web-based technology that powers IVA.
“Adobe is planning to end-of-life Flash. Specifically, we will stop updating and distributing the Flash Player at the end of 2020 and encourage content creators to migrate any existing Flash content to these new open formats.”
What does this mean for QIAGEN Digital Insights and for QIAGEN IVA?
QIAGEN Digital Insights has evolved from the collection of world-class bioinformatics and scientific and clinical content properties, such as Ingenuity, CLC bio, Biobase, OmicSoft, and N-of-One. As such, there has been an effort to streamline the QIAGEN Digital Insights portfolio.
We have taken the opportunity to deprecate the Flash version of IVA while merging its functionality into QIAGEN Clinical Insights (QCI). This way we can streamline the QIAGEN Digital Insights portfolio while preserving the IVA workflows in an HTML5 compliant platform.
During the 2020 transition period, IVA users will have full access to the classic, Flash-based IVA platform. By mid-2020, an updated version of QCI will contain elements supporting many of the existing IVA workflows. Once this version of QCI becomes available, all IVA users will automatically have access to QCI as part of their IVA subscription within 2020. With access to both IVA and QCI, users will be able to learn how to perform IVA workflows within QCI and provide feedback to the development team.
After December 31, 2020, all IVA users must use the QCI platform, as the classic IVA Flash platform will be terminated after that date.
If you have any questions, please contact us at firstname.lastname@example.org.